79990-25-3

Basic information

• Product Name: 1-iodo-3-Methoxy-5-nitrobenzene
• Synonyms: 1-iodo-3-Methoxy-5-nitrobenzene
• CAS NO: 79990-25-3
• Molecular Formula: C₇H₆INO₃
• Molecular Weight: 279.03191
• Mol File: 79990-25-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 84 °C
• Boiling Point: 344.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.893±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-iodo-3-Methoxy-5-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-iodo-3-Methoxy-5-nitrobenzene(79990-25-3)
• EPA Substance Registry System: 1-iodo-3-Methoxy-5-nitrobenzene(79990-25-3)

Safety Data

• Hazardous Substances Data: 79990-25-3(Hazardous Substances Data)

Usage

General Description

1-iodo-3-Methoxy-5-nitrobenzene is a chemical compound with the molecular formula C7H6INO3. It is a pale yellow crystalline solid that is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. 1-iodo-3-Methoxy-5-nitrobenzene is characterized by the presence of a nitro group and an iodo group, which makes it useful in the production of dyes, pigments, and other industrial chemicals. It is also used in organic synthesis as a building block for more complex molecules. Additionally, the methoxy group in the compound makes it useful as a protecting group in organic reactions. Overall, 1-iodo-3-Methoxy-5-nitrobenzene is a versatile chemical that has several industrial and laboratory applications.

Upstream product

• 67-56-1 methanol 
• 6276-04-6 3,5-dinitroiodobenzene 
• 98-95-3 nitrobenzene 
• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 586-10-7 3-methoxy-5-nitroaniline 
• 5327-44-6 3,5-dinitroanisole 
• 124-41-4 sodium methylate 

Downstream Products

• 93398-05-1 4-(3-methoxy-5-nitrophenyl)morpholine 
• 1051899-53-6 4-(3-nitro-5-phenylmethoxy-phenyl)morpholine 
• 1051899-54-7 3-morpholin-4-yl-5-phenylmethoxy-aniline 
• 1051899-52-5 3-morpholin-4-yl-5-nitro-phenol 
• 344324-66-9 1,3-diiodo-5-methoxybenzene 
• 269411-75-8 3-benzyloxy-5-iodo-benzamide 
• 269411-51-0 3-(3-carbamoyl-5-hydroxy-phenyl)-acrylic acid ethyl ester 
• 269411-74-7 3-hydroxy-5-iodo-benzamide 
• 269411-73-6 3-iodo-5-methoxy-benzamide 
• 269411-71-4 3-amino-5-methoxy-benzonitrile 
• 269411-72-5 3-iodo-5-methoxy-benzonitrile 
• 62605-98-5 1-iodo-5-methoxy-phenylamine 
• 861800-86-4 1-chloro-3-iodo-5-methoxybenzene 
• 1333950-32-5 C₉H₆ClNO 

Relevant articles and documents

Synthesis, Biological Evaluation, and Computational Analysis of Biaryl Side-Chain Analogs of Solithromycin

There is an urgent need for new antibiotics to mitigate the existential threat posed by antibiotic resistance. Within the ketolide class, solithromycin has emerged as one of the most promising candidates for further development. Crystallographic studies of bacterial ribosomes and ribosomal subunits complexed with solithromycin have shed light on the nature of molecular interactions (π-stacking and H-bonding) between from the biaryl side-chain of the drug and key residues in the 50S ribosomal subunit. We have designed and synthesized a library of solithromycin analogs to study their structure-activity relationships (SAR) in tandem with new computational studies. The biological activity of each analog was evaluated in terms of ribosomal affinity (Kd determined by fluorescence polarization), as well as minimum inhibitory concentration assays (MICs). Density functional theory (DFT) studies of a simple binding site model identify key H-bonding interactions that modulate the potency of solithromycin analogs.

Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that interfere with the replication of human immunodeficiency virus (HIV) are being pursued with guidance from molecular modeling including free-energy perturbation (FEP) calculations for protein-in

Leukotriene B4 Inhibitors

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD